Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry
To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.
Checked against the public recordLast updated Jun 12, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- M.D. Anderson Cancer Center
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: Patients with peripheral lung tumors (primary or metastatic) that have been or will be ablated via robotic bronchoscopy. Exclusion Criteria: Patients with planned bronchoscopic ablations of peripheral lung tumors that were aborted for technical reasons (ablation was not completed).
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- MD Anderson Cancer CenterHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 12, 2026. Always confirm current availability with the study team.